Literature DB >> 1847591

Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.

V Le Meuth1, N Farjaudon, W Bawab, E Chastre, G Rosselin, P Guilloteau, C Gespach.   

Abstract

HPLC-purified 125I-labeled vasoactive intestinal peptide (VIP) bound in a specific, saturable, and reversible manner to pancreatic plasma membranes isolated from newborn calves, from milk-fed calves at 28 and 119 days, and from weaned calves at 119 days. A series of VIP analogues, including pituitary adenylate cyclase-activating polypeptide (PACAP), displaced 125I-VIP binding and activated adenylate cyclase in the same order of relative potency: PACAP-38 greater than helodermin greater than VIP, PACAP-27 greater than PHM (human peptide with NH2-terminal histidine and COOH-terminal methionine amide). At maximally effective concentrations, these five peptides produced the same two- to threefold increase of adenylate cyclase activity in pancreatic membranes from newborn and 28-day-old calves, and fourfold in ruminant or preruminant animals at 119 days. The activation constant for PACAP-38 ranged from 0.1 to 0.34 nM throughout the postnatal development. Helospectin I and II were three times less potent than VIP in inhibiting 125I-VIP binding. At concentrations up to 0.1 microM, secretin, rat and human growth hormone-releasing factors, glucagon, oxyntomodulin, the truncated form of glucagon-like peptide-1 lacking the 6 NH2-terminal amino acid sequence (TGLP-1), GLP-2, gastric inhibitory peptide, gastrin, CCK, and insulin had no effect on binding. Scatchard plots from 28- and 119-day-old calves were compatible with the presence of two classes of 125I-VIP binding sites: one with a high affinity for VIP and a low binding capacity (Kd = 0.11-0.4 nM, Bmax = 66-174 fmol/mg protein) and the other with a low affinity and high binding capacity. At birth, only one class of binding sites was observed (Kd = 0.4 nM, Bmax = 858 fmol/mg protein). The covalently cross-linked PACAP-preferring 125I-VIP binding site is a glycoprotein of 55 kDa with higher sensitivity to PACAP vs. helodermin and VIP. Our results suggest that calf pancreatic functions might be regulated at an early stage of postnatal development by PACAP receptors linked to cAMP generation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847591     DOI: 10.1152/ajpgi.1991.260.2.G265

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Vasoactive intestinal peptide receptors in rat liver after partial hepatectomy.

Authors:  L G Guijarro; A Couvineau; M S Rodriguez-Pena; M G Juarranz; N Rodriguez-Henche; E Arilla; M Laburthe; J C Prieto
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

2.  Vasoactive intestinal polypeptide-augmented insulin release: actions on ionic fluxes and electrical activity of mouse islets.

Authors:  M A Wahl; S G Straub; H P Ammon
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

3.  Pituitary adenylate cyclase activating polypeptides, PACAP-27 and PACAP-38: stimulators of electrogenic ion secretion in the rat small intestine.

Authors:  H M Cox
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

4.  Characterization of normal breast epithelial cells in primary cultures: differentiation and growth factor receptors studies.

Authors:  P Berthon; G Pancino; P de Cremoux; A Roseto; C Gespach; F Calvo
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.